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Abstract
Background: We analysed in vitro the appearance of commonly used ureteral stents with dual-energy
computed tomography (DECT) and we used these characteristics to optimize the differentiation between
stents and adjacent stone.
Methods: We analysed in vitro a selection of 36 different stents from 7 manufacturers. They were placed in a
self-build phantom model and measured using the SOMATOM® Force Dual Source CT-Scanner (Siemens,
Forchheim, Germany). Each sample was scanned at various tube potentials of 80 and 150 peak kilovoltage
(kVp), 90 and 150 kVp and 100 and 150 kVp. The syngo Post-Processing Suite software program (Siemens,
Forchheim, Germany) was used for differentiation based on a 3–material decomposition algorithm (UA,
calcium, urine) according to our standard stone protocol.
Results: Stents composed of polyurethane appeared blue and silicon-based stents were red on the image.
The determined appearances were constant for various peak kilovoltage (kVp) values. The coloured stent-
stone-contrast displayed on DECT improves monitoring, especially of small calculi adjacent to indwelling
ureteral stents.
Conclusion: Both urinary calculi and ureteral stents can be accurately differentiated by a distinct appearance
on DECT. For the management of urolithiasis patients can be monitored more easily and accurately using
DECT if the stent shows a different colour than the adjacent stone.
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Background
Urolithiasis is a common bothersome condition with a
prevalence of 4–20% and an upward trend is reported in
developed countries [1, 2]. Non-contrast enhanced com-
puted tomography (NCCT) is the standard for diagnos-
ing patients with acute flank pain [3]. Low-dose NCCT
has emerged as the imaging technique of first choice in
the acute setting. It provides both excellent sensitivity of
97% and specificity of 95% for the detection of urinary
calculi [4]. NCCT determines accurately location, size,
density and skin-to-stone distance, all of which are
relevant determinants for treatment decision. With the
introduction of technical innovations like dual-energy
computed tomography (DECT) acquisition of additional
information on chemical stone composition is now
possible. The attenuation difference produced by two
different x-ray energy spectra is utilized to differentiate
uric-acid (UA) calculi from non-uric-acid (non-UA)
stones. The post-processing software applied for analysis
uses a 3-material decomposition algorithm, which char-
acterizes a calculus as a mixture of UA, calcium and
urine. Based on this algorithm, material-specific chro-
matic image-pixels with an attenuation ratio similar to
UA are coloured red, those similar to non-UA stones
appear blue. This classification is achieved with high
accuracy, which is supported by a reported sensitivity of
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up to 100% [5–12]. The fact can be decisive for opti-
mal management as in case of UA stones pharmaco-
logical chemolitholysis is preferred to interventional
approaches [3].
Of note, ureteral stents are also assigned a specific
colour according to their material composition on
DECT. The imaging of small stones adjacent to a ur-
eteral stent is a common pitfall in the current diagnostic
assessment. The option to display stent and stone in
contrasting colour may help to optimize the detection.
The colour-coded characteristics of calculi based on
chemical composition are well documented, whereas for
ureteral stents they do not. The determinants underlying
the phenomenon of red and blue stents on DECT scans
have not been elucidated yet. In the current work it was
our main objective to characterize in vitro the appear-
ance of different stents from various manufacturers
using DECT.
Methods
In vitro setting
We purchased 36 commonly used stents from 7 manu-
facturers and analysed them on the third generation
SOMATOM® Force Dual Source CT-Scanner (Siemens,
Forchheim, Germany). We used a phantom model meas-
uring 45 cm × 20 cm × 20 cm (height x width x depth)
and filled it with water at body temperature (36 °C)
(Fig. 1). The model itself and experimental settings had
no influence on CT performance and analysis. Stents
were fixed with clips, spanned throughout the phantom
model and consecutive measurements were performed.
Each sample was scanned at various tube potentials of
80 and 150 peak kilovoltage (kVp), 90 and 150 kVp and
100 and 150 kVp. We affixed a calculus of 2 mm in
diameter of known chemical composition (calcium oxal-
ate monohydrate; blue on DECT scan) to blue and red
stents and repeated measurements.
CT protocol and post processing
The images were acquired on a SOMATOM® FORCE
Siemens computed tomography (CT) scanner (Siemens,
Forchheim, Germany) in dual-energy mode. The patients
underwent imaging with 100/Sn150 kVp reflecting our
current institutional dual-energy protocol. Continuous
non-contrast images were obtained from the level of the
diaphragm to the pubic symphysis. A slice thickness of
4 mm and interval of 4 mm were chosen to be consistent
with our clinical practice. The images were recon-
structed on a multimodality WorkPlace (Siemens) using
CT syngo Post-Processing Suite software, version VA
50A (Siemens). Reconstructions used a 0.75-mm slice
thickness and 0.7-mm interval, with a QR40 convolution
kernel for optimal data analysis. DECT allows differenti-
ating between uric acid (UA) and non-UA stones, which
are colour-coded based on a post-processing algorithm.
The syngo Post-Processing Suite software program utilizes
a 3-material (UA, calcium, and urine) decomposition algo-
rithm to assign colour (red or blue) based on the ratio of
X-ray attenuations from the two tube potentials. Materials
that more closely resemble the dual-energy characteristics
(DEC) of UA stones are depicted in red and those that
more closely resemble the DEC of non-UA stones are
depicted in blue.
Results
Results are demonstrated in Fig. 2a. All polyurethane-
based stents showed a blue appearance on DECT,
whereas stents composed of silicone were red. The
assigned colours were constant over various kVp values.
The determined colour according to material compos-
ition of various stents from the same manufacturer was
consistent throughout our measurements (Table 1). As
shown in Fig. 2b, placing a pure calcium oxalate mono-
hydrate stone (blue) of 2 mm in size next to a ureteral
stent of blue colour makes it difficult to discern the frag-
ment on both coronal and sagittal reformatted DECT
Fig. 1 A container was filled with water at body temperature (36 °C). Stents were fixed with clips at both ends and spanned throughout the
phantom model for measurements
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images. Now, using a silicone-based stent, which appears
red on DECT, the presence of the stone could be easily
detected due to a clear stent-stone-contrast.
Discussion
Information on chemical stone composition optimizes
management of urolithiasis in many ways. As mentioned
above, DECT assures identification of UA stones with
high accuracy, thus efficient chemolitholysis should be
preferred rather than interventional treatment, if it is
clinically appropriate and safe. However, the overall
incidence of UA stones was estimated to be 11.7% for
men and 7% for women [13]. Thus, the clinical impact
on management is actually rather low. Furthermore, the
unique ability to determine stone types may prevent
inefficient treatment options. Extracorporeal shockwave
lithotripsy (ESWL) achieves good results for renal stones
≤20mm, but shockwave-resistant stones composed of
calcium oxalate monohydrate or cystine are known
negative predictors for success [14]. Both stone types
can be identified with high diagnostic accuracy using
DECT [15]. In these cases multiple ineffective procedures
can be avoided in favour of a more effective treatment
modality such as percutaneous nephrolithotomy (PNL).
A distinct appearance of ureteral stents on DECT has
been observed, but a systematic analysis of this
phenomenon is lacking [16]. In the current study we
investigated in vitro a random selection of 36 various
samples from 7 manufacturers and we were able to
match appearance (blue or red) to material composition
Fig. 2 a. Results acquired for various tube potentials (80/150 kVp; 90/150 kVp; 100/150 kVp). Respective Hounsfield units (HU) were measured and
plotted. Stents above the cut-off of 1,15 appeared blue and samples below the cut-off appeared red. Reference values for known stone types are
depicted as well. Polyurethane-based samples were blue, silicone-based stents were red. b. A pure calcium oxalate monohydrate stone of 2 mm
(blue) was affixed to a blue and red stent on DECT. The enhanced stent-stone-contrast obtained for the red stent allows clear differentiation of
the stone from the adjacent stent. For the blue stent a contour irregularity of the stent is indicative of stone presence, better displayed on
coronal than sagittal images
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of a stent. In our setting polyurethane-based stents were
always blue on DECT, stents composed of silicone
appeared always red. We further demonstrated that an
enhanced stent-stone-contrast by selecting a stent in a
different colour than the adjacent stone facilitates safe
and easy detection, even for 2 mm calculi. This en-
hanced stent-stone-contrast allows clear differentiation
in both coronal and sagittal images. Without colour
coding, as in NCCT, only a contour irregularity may be
suggestive of an adjacent stone, which becomes specula-
tive when calculi decrease in size. This diagnostic
obstacle may be overcome using color-coding based on
a post-processing algorithm as applied in DECT. We
demonstrated that a pure calcium oxalate monohydrate
stone (blue) of 2 mm could be clearly differentiated from
a silicon-based stent (red). Next to a blue stent, the
presence of the stone was indicative by a poorly defined
irregularity, which was more prominent on the coronal
scan. The analysis of other 2 mm stones with different
composition but a distinct colour on DECT scans, could
always be detected accurately when the stent appeared
in contrasting colour.
This feature may be of value in various clinical scenar-
ios for the management of urolithiasis. The advantage of
DECT technology aids urologists in stent selection
according to stone appearance and assures accurate
monitoring of stone patients. It has to be acknowledged,
that stenting is indicated only in case of obstructive
pyelonephritis, anuria and analgesia not achieved medic-
ally. The impact of our findings still needs to be evalu-
ated for the clinical management.
The early results of DECT imaging for the manage-
ment of urolithiasis are promising, however, due to the
infancy of this technology relevant issues still need to be
addressed. Certain pitfalls have been reported including
reduced specificity for small calculi < 3 mm and patients
with large body habitus [17]. With the development of
third-generation scanners and modification of protocol
settings and post-processing the capacity and potential
of the technology is still advancing [18].
Certain limitations of this study need to be acknowl-
edged. First of all, although we present the analysis of
the largest stent collection to date with convincing
consistency, we cannot exclude that stents from different
manufacturers may display a diverse phenotype. Certain
coatings might have a profound impact on appearance
on DECT. Second, we present mainly in vitro data.
Prospective, clinical trails are necessary to confirm our
first results in stone patients and to evaluate the true
benefit for management.
Conclusions
Polyurethane-based stents are blue and stents composed
of silicone appear red using DECT imaging. The enhanced
Table 1 A random selection of 36 various stents was purchased
from 7 manufacturers. Material composition and reference
numbers for each model are displayed. Stents are classified
according to their appearance as red or blue on DECT
Manufacturer RED BLUE
Uromed Hydropur (polyurethane,
4640–28)
Hydropur (polyurethane,
4687–28)
Heparius (polyurethane,
4377–28)
Heparius (polyurethane,
4387–28)
Urotech Yellow-Star (polyurethane,
TU-360628)
Yellow-Star (polyurethane,
EP-360628)
Green-Star (polyurethane,
EG-480628)
White-Star (polyurethane,
ES-370628)
White-Star (polyurethane,
ES-570730)
Cook C-Flex Towers (TPE,
037732)
Universa Soft (TPE,
USH-722-T1)
Black Silicone (silicone,
133,624)
Universa UFH (polyurethane,
UFH-772-T1)
Resonance (metal,
RMS-060022-R)
Rüsch Superglide DD
(polyurethane, 334,841)
Superglide integral
(polyurethane, 334,248)
Integral Stent Set
(polyurethane, 334,201)
DD-Ureterstent
(polyurethane, 334,801)
Optimed Optisoft (polyurethane,
3004–2400)
Optipur (polyurethane,
3034–2400)
Optisplint (polyurethane,
3064–2400)
Carbosoft (polyurethane,
3090–2400)
Coloplast/
Porges
Vortek Tumor Stent
(Vortek, BCCG75)
Vortek (Vortek, ACB576)
Vortek Hydrogel (Vortek,
BCFA75)
Vortek Hydrogel (Vortek,
BNFA75)
Vortek Mono-J (Vortek,
ACA207)
Silicone (silicone, AJ4275)
Silicone (silicone, AJ4A75)
Silikon Pyelostent (silicone,
AJ4Y85)
Silikon Stenostent (silicone,
AJ4W85)
PU-R (polyurethane,
AC4D75)
PU-R (polyurethane,
AC4B75)
PU-S (polyurethane,
AC4274)
Biosoft Duo (polyurethane,
BNAA75)
IMP Tumorstent (polyurethane,
S137996070300)
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stent-stone-contrast using DECT imaging is an additional
feature that may be helpful for stent selection. Whenever
available, it can contribute to an easy and accurate monitor-
ing of stone patients. The coloured stent-stone-contrast
displayed on DECT improves detection, especially of small
calculi < 3mm next to indwelling ureteral stents. Wherever
DECT is available, urologists are encouraged to screen for
blue and red stents in their institution and to choose
ureteral stents according to stone appearance.
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